THAT LOW-LEVEL HUM OF WORRY THAT JUST NEVER SHUTS OFF.

THAT LOW-LEVEL HUM OF WORRY THAT JUST NEVER SHUTS OFF.

Regular CBD didn't touch it. Here's what's actually different about CBDA — and why it works on anxiety when other hemp products don't.

SEE WHAT WORKS →
100-DAY MONEY-BACK GUARANTEE

100-DAY MONEY-BACK GUARANTEE

Full refund, no questions asked, no return required

THIRD-PARTY LAB TESTED

THIRD-PARTY LAB TESTED

Every batch tested for potency, purity, and contaminants

FREE SHIPPING OVER $70

FREE SHIPPING OVER $70

Ships in 2 business days

FOUNDED BY A PhD AND MD

FOUNDED BY A PhD AND MD

Formulated by Dr. Luigi Bertoli (MD) and Dr. Colin Reily (PhD)

AS SEEN IN

It's not dramatic. It's just always there.

It's not panic attacks. It's the low-grade tension that shows up by mid-morning and doesn't really leave. Feeling reactive over things that didn't used to bother you. A tightness in your chest or shoulders at the end of the day. Your mind still running through the list even when you're sitting still. You're managing — but there's a version of your day that feels calmer than this, and you haven't found what gets you there.

A glass of wine

A glass of wine

Works for an hour

Worse the next morning

CBD gummies or oil

CBD gummies or oil

Felt nothing noticeable

No real baseline change

Prescription options

Prescription options

Didn't want the side effects

Or the dependency

Why regular CBD barely touches anxiety

✕

Standard CBD

Heating during production destroys CBDA — the raw compound the hemp plant actually makes. What reaches you is a degraded form your body absorbs poorly. Low absorption means a weak signal — which is why the effect feels mild or nonexistent.

✓

Natural Dos CBDA

Low-temperature purification keeps CBDA intact, exactly as the plant produced it. Your body absorbs it over 500% better than standard CBD. A stronger signal means you actually feel the difference.

What CBDA actually does

Quiets the stress response

Quiets the stress response

CBDA works with your endocannabinoid system — the network that regulates how your body reacts to stress. When that system is running well, smaller things stay smaller. You don't stop caring. You just stop overreacting.

Same pathways, different mechanism

Same pathways, different mechanism

CBDA activates serotonin receptors that regulate mood and stress. Unlike SSRIs, it doesn't flood the system or block reuptake — it sensitizes the receptor to the serotonin you already have. Same pathway, different mechanism. No prescription, no dependency, no adjustment period.

Calm without the fog

Calm without the fog

It doesn't sedate you or flatten you out. What most people describe is more like a volume dial turned down — the edge comes off, the baseline lowers, and you feel more like yourself. Most notice it within 30–60 minutes.

REAL CUSTOMERS

HEAR IT FROM THEM.

FIND YOUR CALM →

Scientific References

NaturalDos™ is not endorsed by, sponsored by, or affiliated with any of these organizations.

ACS Chemistry for Life
British Pharmacological Society
PAIN Journal
Springer
Scientific Reports
Nature Portfolio
1. Formato, M. et al. (2020). Cannabidiolic-Acid (CBDA): A Unique Compound of Cannabis. Molecules, 25(21), 4936.
2. Bolognini, D. et al. (2013). Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. British Journal of Pharmacology, 168(6), 1456–1470.
3. Rock, E.M. et al. (2020). Cannabidiol and cannabidiolic acid reduce nausea and vomiting. Cannabis and Cannabinoid Research, 5(3), 191–198.
4. Takeda, S. et al. (2008). Cannabidiolic acid as a selective cyclooxygenase-2 inhibitory component in cannabis. Drug Metabolism and Disposition, 36(9), 1917–1921.
5. Rock, E.M. et al. (2018). Effect of cannabidiolic acid and ∆9-tetrahydrocannabinol on carrageenan-induced hyperalgesia and edema. Psychopharmacology, 235, 3259–3271.
6. Anderson, L.L. et al. (2019). Pharmacokinetics of phytocannabinoid acids and anticonvulsant effect of cannabidiolic acid in a mouse model of Dravet Syndrome. Journal of Natural Products, 82(11), 3047–3055.
7. Pertwee, R.G. et al. (2018). Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5-HT1A receptor-mediated suppression of nausea. British Journal of Pharmacology, 175(1), 100–112.
8. Zhu, H.J. et al. (2006). Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana. Journal of Pharmacology and Experimental Therapeutics, 317(3), 850–857.
9. Pellesi, L. et al. (2018). European Journal of Clinical Pharmacology: Pharmacokinetics and tolerability of oral cannabis preparations in patients with medication overuse headache.
10. Ujváry, I. & Hanuš, L. (2016). Human metabolites of cannabidiol: A review on their formation, biological activity, and relevance in therapy. Cannabis and Cannabinoid Research, 1(1), 90–101.
11. Rock, E.M. & Parker, L.A. (2013). Effect of low doses of cannabidiolic acid and ondansetron on LiCl-induced conditioned gaping in rats. British Journal of Pharmacology, 169(3), 685–692.
12. Takeda, S. et al. (2014). Down-regulation of cyclooxygenase-2 (COX-2) by cannabidiolic acid in human breast cancer cells. Journal of Toxicological Sciences, 39(5), 711–716.
13. De Petrocellis, L. et al. (2011). Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. British Journal of Pharmacology, 163(7), 1479–1494.
14. Navarro, G. et al. (2020). Cannabigerol action at cannabinoid CB1 and CB2 receptors and CB1–CB2 heteroreceptor complexes. Frontiers in Pharmacology, 11, 422.
15. Shannon, S. et al. (2019). Cannabidiol in anxiety and sleep: A large case series. The Permanente Journal, 23, 18–041.
16. Suraev, A.S. et al. (2020). Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies. Sleep Medicine Reviews, 53, 101339.
17. Kesner, A.J. & Lovinger, D.M. (2020). Cannabinoids, endocannabinoids and sleep. Frontiers in Molecular Neuroscience, 13, 125.
18. Murillo-Rodriguez, E. et al. (2006). Anandamide modulates sleep and memory in rats. Brain Research, 1075(1), 108–115.
19. Pacher, P. et al. (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews, 58(3), 389–462.
20. Russo, E.B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 163(7), 1344–1364.